

## Viracta Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Nov. 1, 2021 /PRNewswire/ -- [Viracta](#) Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is scheduled to present and host one-on-one meetings at the following upcoming investor conferences:

### **Credit Suisse 30<sup>th</sup> Annual Healthcare Conference (virtual)**

Conference Dates: November 8 – 12, 2021  
Presentation Date: November 11, 2021  
Presentation Time: 1:50 PM ET  
Format: Corporate presentation

### **Jefferies London Healthcare Conference (in-person)**

Conference Dates: November 16 – 17, 2021  
Presentation Date: November 17, 2021  
Presentation Time: 10:40 AM GMT/ 5:40 AM ET  
Format: Corporate presentation

### **Piper Sandler 33<sup>rd</sup> Annual Healthcare Conference (virtual)**

Conference Dates: November 29 – December 2, 2021  
Presentation Available: November 22, 2021, at 10:00 AM ET  
Format: Corporate presentation

### **Evercore ISI 4<sup>th</sup> Annual HealthCONx Conference (virtual)**

Conference Dates: November 29 – December 2, 2021  
Presentation Date: December 2, 2021  
Presentation Time: 3:55 PM ET  
Format: Fireside chat

A live webcast of each of the presentations will be available under "Events and Webcasts" in the Investors section of the Viracta website at <https://viracta.investorroom.com/events-and-webcasts>. Replays of each webcast will be archived on the Viracta website for at least 30 days following the presentation.

### **About Viracta Therapeutics, Inc.**

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in two Phase 2 clinical trials for EBV-positive (EBV<sup>+</sup>) lymphoma and one Phase 1b/2 trial in patients with EBV<sup>+</sup> nasopharyngeal carcinoma and other EBV<sup>+</sup> solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers. For additional information please visit [www.viracta.com](http://www.viracta.com).

### **Investor Relations Contact:**

Ashleigh Barreto  
Head of Investor Relations and Corporate Communications  
Viracta Therapeutics, Inc.  
[abarreto@viracta.com](mailto:abarreto@viracta.com)

SOURCE Viracta